New Anti-VEGF Drugs in Ophthalmology

Author(s): Claudio Campa*

Journal Name: Current Drug Targets

Volume 21 , Issue 12 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab.

Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.

Keywords: Anti-VEGF, conbercept, brolucizumab, port delivery system, ranibizumab, abicipar pegol, faricimab.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 12
Year: 2020
Page: [1194 - 1200]
Pages: 7
DOI: 10.2174/1389450121666200428101738
Price: $65

Article Metrics

PDF: 66